Total
USD $0.00
 
China

Company Overview of Hubei Biocause Pharmaceutical Co., Ltd. (天茂实业集团股份有限公司)

An EMIS Company Report EMIS is an ISI Emerging Markets Group Company Company Description

The company is a listed company whose operation is across chemical and pharmaceutical industries. The company business has four large sections: new energy, synthetic resins, bulk drugs, intermediates and pharmaceutical preparations with more than 100 kinds of products. Company is mainly engaged in pharmaceutical intermediates, bulk drugs and pharmaceutical preparations and other products, R&D and manufacturing as well as dimethyl ether and other new energy manufacturing. In the field of raw material production for anti-inflammatory drugs, the company owns ibuprofen manufacturing equipment with annual output of 3800 tons, which rank third in the world, the first in China. Many of its bulk drugs have passed FDA site inspection and COS certification. The company is one of high-tech enterprises of Hubei province.

Need a report on this company? USD 29.95 Industry: Pharmaceutical and Medicine Manufacturing Available in: English & Chinese Format: PDF Download Most recent financial data: 2017 Buy full report

Report contents

On purchasing the report for this company you will have access to a PDF containing the most recent data for Hubei Biocause Pharmaceutical Co., Ltd. from the EMIS database.

To give you a clear idea of the information provided, you can download a sample report for a different company below.

Download a sample report
NAICS Industry Classification
Main Activities: Pharmaceutical and Medicine Manufacturing
Contact Information

Headquarters
132 Yangwan Rd. Jingmen Hubei
Jingmen; Hubei; Postal Code: 448000

Tel: 86-724-222
Fax: 86-724-221

Email:
@biocause.net

Website:
http://www.biocause.com

Basic Information
Total Employees:
3,175 (2016)
Outstanding Shares:
Provided in the purchased report
Registered Capital:
Provided in the purchased report
Financial Auditors:
Provided in the purchased report
Incorporation Date:
December 31, 1993
Key Executives
Provided in the purchased report
Chairman
Provided in the purchased report
Director
Provided in the purchased report
Director
Provided in the purchased report
Director
Provided in the purchased report
Director
More
Ownership Details
Xinliyi Group Co., Ltd.
23.78%
Chen Lin Fang
0.63%
Li Fu Qiao
0.36%
中融国际信托有限公司-中融-金弛一号证券投资集合资金信托计划
0.31%
Ma Yan Lin
0.3%
More
Subsidiaries
Hubei Baike Hengdi Pharmaceutical Co., Ltd.
100%
Jingmen Hecheng Commerce Ltd.
100%
Jingmen day Reed Investment Co.
100%
More
M&A deals (Not included in report)

Report contents

On purchasing the report for this company you will have access to a PDF containing the most recent data for Hubei Biocause Pharmaceutical Co., Ltd. from the EMIS database.

To give you a clear idea of the information provided, you can download a sample report for a different company below.

Download a sample report
Key Financial Highlights
Annual growth percentages* for latest two years in USD terms. Absolute financial data is included in the purchased report.
Net sales revenue
21.44%
Total operating revenue
-45.84%
Operating profit (EBIT)
17.01%
EBITDA
16.97%
Net Profit (Loss) for the Period
8.71%
Total assets
21.88%
Total equity
18.54%
Operating Profit Margin (ROS)
-16.84%
Net Profit Margin
-48.07%
Return on Equity (ROE)
-1.24%
Debt to Equity Ratio
16.5%
Quick Ratio
789.75%
Cash Ratio
133.43%
* Growth figures are affected by the currency rate changes.
Company News (Not included in report)
Enterprise ACCESS

If you need regular and ongoing access to company information, you should consider a subscription to the full EMIS service.

EMIS company profiles are part of a larger information service where that combines company, industry and country data and analysis for over 125 emerging markets on a unique information platform.

Request a demonstration of the EMIS service

To view more information, Request a demonstration of the EMIS service